

# Anti-CD38 Antibody Treating Evans Syndrome

NCT06014775

|                   |  |
|-------------------|--|
| <b>Status</b>     | RECRUITING   |
| <b>Phase</b>      | Phase 2  |
| <b>Sponsor</b>    | Institute of Hematology & Blood Diseases Hospital, China |
| <b>Enrollment</b> | 10 participants  |

## Plain Language Summary

This trial is testing an anti-CD38 antibody treatment for people with Evans syndrome — a rare autoimmune condition where the immune system attacks its own red blood cells and platelets at the same time, causing anemia and bleeding risk. This study targets people whose disease has not responded to standard treatments.

**\*\*You may be eligible if...\*\***

- You are 18 or older
- You have been diagnosed with primary Evans syndrome
- Your blood counts are significantly low (platelets <30 or hemoglobin <100g/L, or you have symptomatic anemia)
- You have not responded to or have relapsed after corticosteroids and at least one second-line treatment
- Your immune system is actively attacking red blood cells (positive DAT test, active hemolysis)
- Your liver, kidney, and heart function are within acceptable limits

**\*\*You may NOT be eligible if...\*\***

- You have secondary Evans syndrome (caused by another condition)
- You have previously received anti-CD38 antibody therapy
- You have another serious uncontrolled disease (e.g., organ failure or active cancer)
- You recently used certain immunosuppressive treatments without adequate washout time

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

### Inclusion (12)

- Male or female aged ≥18 years.
- Prior to enrollment, a clinical diagnosis of primary Evans syndrome was made.
- Platelet count < 30×10<sup>9</sup>/L or Hb < 100g/L or symptomatic anemia within 48 hours before the first administration of study drug;
- Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy or those who cannot choose other second-line therapy;
- If receiving emergency care for ES, treatment should be stopped >2 weeks before first dose.

... and 7 more (see full listing online)

### Exclusion (14)

- Secondary Evans syndrome. Received any treatment of anti-CD38 antibody drug
- Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;
- HIV positive;
- Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;
- Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.

<https://clinicaltrials.gov/study/NCT06014775>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 9 more (see full listing online)

## Locations (1 total)

---

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China

---

<https://clinicaltrials.gov/study/NCT06014775>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).